
    
      To assess the safety and tolerability of single and repeated ascending doses of CHF 6001 in
      healthy volunteers and to investigate the pharmacokinetic (PK) profile of CHF 6001 and its
      metabolites CHF 5956 and CHF 6095.
    
  